UNSPSC 51313217: Diphenylpyraline hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9FU7F1E87, chemically known as piperidine, 4- (diphenylmethoxy)-1-methyl-, hydrochloride but more generally known as diphenylpyraline hydrochloride, which bears US NIH Compound Identifier 3103. European Medicines Agency schedules Diphenylpyraline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01778MIG.

UNSPSC 51313217 Diphenylpyraline hydrochloride is a Commodity code with minimal recent activity aligned to its narrow pharmaceutical specification. The code nominally describes a specific antihistamine active pharmaceutical ingredient; however, the recent state and local opportunities posted under it reflect broader pharmaceutical procurement — generic multi-source drugs, naloxone, and direct-to-manufacturer prescription programs — rather than diphenylpyraline hydrochloride as a discrete product line. State and local buyers actually soliciting under this code span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances (MMCAP), each pursuing routine drug supply, overdose-response medications, or pharmacy benefit strategy.

The geographic distribution and recent activity focus on Florida and Minnesota, with Texas HHS conducting exploratory market intelligence. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS) on June 30, 2026 (with a due date of July 26, 2023 — a noted discrepancy in the source) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to Seminole County Community Health Building in Sanford, with a fixed-fee basis and two-year initial term plus one-year renewal option. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) posted January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson), with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Texas HHS issued an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer pharmacy benefit programs without specified budget or timeline. The mismatch between the code's specificity and the scope of actual solicitations suggests limited true demand for diphenylpyraline hydrochloride as a standalone product in state and local procurement right now.